247 related articles for article (PubMed ID: 31517642)
1. Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast.
Vranic S; Senarathne W; Stafford P; Poorman K; Pockaj BA; Gatalica Z
Appl Immunohistochem Mol Morphol; 2020 Oct; 28(9):661-668. PubMed ID: 31517642
[TBL] [Abstract][Full Text] [Related]
2. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
[TBL] [Abstract][Full Text] [Related]
3. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
Krieger T; Pearson I; Bell J; Doherty J; Robbins P
Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
Sabari JK; Leonardi GC; Shu CA; Umeton R; Montecalvo J; Ni A; Chen R; Dienstag J; Mrad C; Bergagnini I; Lai WV; Offin M; Arbour KC; Plodkowski AJ; Halpenny DF; Paik PK; Li BT; Riely GJ; Kris MG; Rudin CM; Sholl LM; Nishino M; Hellmann MD; Rekhtman N; Awad MM; Drilon A
Ann Oncol; 2018 Oct; 29(10):2085-2091. PubMed ID: 30165371
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
Chen Y; Liu Q; Chen Z; Wang Y; Yang W; Hu Y; Han W; Zeng H; Ma H; Dai J; Zhang H
J Exp Clin Cancer Res; 2019 May; 38(1):193. PubMed ID: 31088500
[TBL] [Abstract][Full Text] [Related]
6. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.
Yang S; Leone DA; Biswas A; Deng A; Jukic D; Singh R; Sundram U; Mahalingam M
Hum Pathol; 2018 Dec; 82():206-214. PubMed ID: 30120967
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and Predictive Value of PD-L1 Status in Real-World Non-Small Cell Lung Cancer Patients.
Tseng JS; Yang TY; Wu CY; Ku WH; Chen KC; Hsu KH; Huang YH; Su KY; Yu SL; Chang GC
J Immunother; 2018; 41(6):292-299. PubMed ID: 29683890
[TBL] [Abstract][Full Text] [Related]
8. Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report.
Fang C; Zhang C; Zhao WQ; Hu WW; Wu J; Ji M
BMC Med Genomics; 2019 Oct; 12(1):136. PubMed ID: 31619231
[TBL] [Abstract][Full Text] [Related]
9. Recurrent genetic alterations and biomarker expression in primary and metastatic squamous cell carcinomas of the vulva.
Xing D; Liu Y; Park HJ; Baek I; Tran H; Cheang G; Novo J; Dillon J; Matoso A; Farmer E; Cheng MA; Tsai YC; Lombardo K; Conner MG; Vang R; Hung CF; Wu TC; Song W
Hum Pathol; 2019 Oct; 92():67-80. PubMed ID: 31437519
[TBL] [Abstract][Full Text] [Related]
10. Composition of the immune microenvironment differs between carcinomas metastatic to the lungs and primary lung carcinomas.
Senarathne W; Vranic S; Xiu J; Rose I; Gates P; Gatalica Z
Ann Diagn Pathol; 2018 Apr; 33():62-68. PubMed ID: 29566951
[TBL] [Abstract][Full Text] [Related]
11. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites.
Yoshimura K; Inoue Y; Karayama M; Tsuchiya K; Mori K; Suzuki Y; Iwashita Y; Kahyo T; Kawase A; Tanahashi M; Ogawa H; Yokomura K; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Lung Cancer; 2019 Aug; 134():202-209. PubMed ID: 31319982
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.
Inoue Y; Yoshimura K; Mori K; Kurabe N; Kahyo T; Mori H; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Oncotarget; 2016 May; 7(22):32113-28. PubMed ID: 27050074
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages: An Assessment of 245 Primary and 40 Metastatic Tumors.
Dill EA; Gru AA; Atkins KA; Friedman LA; Moore ME; Bullock TN; Cross JV; Dillon PM; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):334-342. PubMed ID: 28195880
[TBL] [Abstract][Full Text] [Related]
15. Loss of heterozygosity of p53, BRCA1, VHL, and estrogen receptor genes in breast carcinoma: correlation with related protein products and morphologic features.
Otis CN; Krebs PA; Albuquerque A; Quezado MM; San Juan X; Sobel ME; Merino MJ
Int J Surg Pathol; 2002 Oct; 10(4):237-45. PubMed ID: 12490973
[TBL] [Abstract][Full Text] [Related]
16. [Detection and Significance of Molecular Markers in Immunotherapy and Targeted Therapy of Colorectal Cancer in Tibet].
Luo HH; Liu BY; Huo Z; BIANbazhaxi ; Wang Q; DUObula ; NImazhuoma ; DA Z; Wang H; Guo PP
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2024 Apr; 46(2):184-192. PubMed ID: 38686714
[TBL] [Abstract][Full Text] [Related]
17. Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer.
Yang CY; Lin MW; Chang YL; Wu CT
Cancer Biomark; 2017 Dec; 21(1):211-220. PubMed ID: 29036791
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC).
Jiang L; Su X; Zhang T; Yin X; Zhang M; Fu H; Han H; Sun Y; Dong L; Qian J; Xu Y; Fu X; Gavine PR; Zhou Y; Tian K; Huang J; Shen D; Jiang H; Yao Y; Han B; Gu Y
Oncotarget; 2017 Apr; 8(16):26845-26857. PubMed ID: 28460468
[TBL] [Abstract][Full Text] [Related]
19. Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status.
Po JW; Ma Y; Balakrishna B; Brungs D; Azimi F; de Souza P; Becker TM
PLoS One; 2019; 14(2):e0211866. PubMed ID: 30735560
[TBL] [Abstract][Full Text] [Related]
20. A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses.
Boyle TA; Quinn GP; Schabath MB; Muñoz-Antonia T; Saller JJ; Duarte LF; Hair LS; Teer JK; Chiang DY; Leary R; Wong CC; Savchenko A; Singh AP; Charette L; Mendell K; Gorgun G; Antonia SJ; Chiappori AA; Creelan BC; Gray JE; Haura EB
Cancer Med; 2020 Jan; 9(1):225-237. PubMed ID: 31747139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
